Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Bought by Kennedy Capital Management LLC

Kennedy Capital Management LLC boosted its stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) by 12.7% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 436,506 shares of the biopharmaceutical company’s stock after purchasing an additional 49,265 shares during the period. Kennedy Capital Management LLC’s holdings in Arbutus Biopharma were worth $1,126,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Arbutus Biopharma during the 1st quarter worth about $266,000. BNP Paribas Financial Markets lifted its stake in Arbutus Biopharma by 19.7% in the 1st quarter. BNP Paribas Financial Markets now owns 349,435 shares of the biopharmaceutical company’s stock valued at $902,000 after buying an additional 57,390 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Arbutus Biopharma by 351.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 19,400 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 15,104 shares in the last quarter. SG Americas Securities LLC lifted its stake in Arbutus Biopharma by 15.3% in the 4th quarter. SG Americas Securities LLC now owns 46,172 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 6,117 shares in the last quarter. Finally, Premier Path Wealth Partners LLC raised its holdings in Arbutus Biopharma by 37.4% in the 1st quarter. Premier Path Wealth Partners LLC now owns 30,500 shares of the biopharmaceutical company’s stock valued at $79,000 after acquiring an additional 8,300 shares during the last quarter. 43.79% of the stock is owned by institutional investors and hedge funds.

Arbutus Biopharma Stock Performance

Arbutus Biopharma stock opened at $3.77 on Thursday. Arbutus Biopharma Co. has a fifty-two week low of $1.69 and a fifty-two week high of $3.98. The firm has a 50 day moving average price of $3.38 and a 200 day moving average price of $2.95. The company has a market capitalization of $711.47 million, a PE ratio of -8.57 and a beta of 1.96.

Arbutus Biopharma (NASDAQ:ABUS) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). Arbutus Biopharma had a negative net margin of 572.81% and a negative return on equity of 62.68%. The firm had revenue of $1.53 million during the quarter, compared to the consensus estimate of $2.16 million. As a group, equities research analysts forecast that Arbutus Biopharma Co. will post -0.39 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on ABUS. Chardan Capital reiterated a “buy” rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a report on Wednesday, June 5th. JMP Securities restated a “market outperform” rating and set a $4.00 price target on shares of Arbutus Biopharma in a report on Thursday, April 4th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a report on Thursday, June 6th.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.